logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Neuro-Oncology Unit

imatge Central Grup Recerca

Scientific Team

Introduction

 

the Unit of Neuro-Oncology is focused in the treatment of brain tumors and
the neurological complications related with cancer and cancer treatments. This is working since
2000 and, during this period has established a fluid network between different medical
specialties. Product of this interaction, and in parallel with the clinical daily activity, has been
rising the research activity of the Unit, at clinical and preclinical level. The aim of the Unit is
create a recognized research group to consolidate our investigation work and the networks
established with other research groups in and outside of the institution.

The Unit of Neuro-Oncology is focused in the treatment of brain tumors and the neurological complications related with cancer and cancer treatments. The aim of the Unit is to create a recognized research group to consolidate previous investigation work and the networks established with other research groups in and outside of the institution.



Research lines

 

1. Clinical efficacy assessment of new drugs and new treatment approaches against
Gliomas and Meningiomas
2. Chemotherapy-induced peripheral neuropathies
3. Cancer and Cognition
4. Leptomeningeal Metastasis
5. Survival Prognostic Factors involved in central nervous system tumors
6. Prevention and personalized treatment of brain metastases: development of new
therapies based on prevention and prognosis target biomarkers
  • 1. Clinical efficacy assessment of new drugs and new treatment approaches againstGliomas and Meningiomas
  • 2. Chemotherapy-induced peripheral neuropathies
  • 3. Cancer and Cognition
  • 4. Leptomeningeal Metastasis
  • 5. Survival Prognostic Factors involved in central nervous system tumors6. Prevention and personalized treatment of brain metastases: development of newtherapies based on prevention and prognosis target biomarkers

Five most recent papers published:

  • Oncotarget. 2015 Oct 19. doi: 10.18632/oncotarget.5471 [Epub ahead of print].FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. 
  • Neuro Oncol. 2015 Sep 27. pii: nov197. [Epub ahead of print]. Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. 
  • Eur Radiol. 2015 Jul 19. [Epub ahead of print]. Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients.
  • Clin Exp Metastasis. 2015 Apr;32(4):383-91. doi: 10.1007/s10585-015-9716-3. Epub 2015 Mar 21. Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. 
  • J Thorac Oncol. 2015 Jan;10(1):38-45. doi: 10.1097/JTO.0000000000000345. Cognitive and brain structural changes in a lung cancer population. 


Five most cited papers:

  • Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77. doi: 10.1016/j.critrevonc.2011.04.012. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
  • Br J Cancer. 2009 Dec 15;101(12):1995-2004. doi: 10.1038/sj.bjc.6605411. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
  • Ann Oncol. 2013 Feb;24(2):454-62. doi: 10.1093/annonc/mds329. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.
  • Cancer. 2013 Jan 15;119(2):438-44. doi: 10.1002/cncr.27732. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
  • Exp Neurol. 2010 Jun;223(2):599-608. doi: 10.1016/j.expneurol.2010.02.006. Neurophysiological, histological and immunohistochemical characterization of bortezomib induced neuropathy in mice.

Agency: Fondos Investigación Sanitaria PI15/01303

Title: Estudio exploratorio sobre la etiopatogenia, biomarcadores de riesgo y mecanismosimplicados en la regeneración de la neuropatía inducida por platinos

IP: Jordi Bruna

N Participants: 5

Period: 2015-2018

Amount: 86515

 

Agency: Fondos Investigación Sanitaria PI14/00336

Title: Prevención y tratamiento personalizado de la metástasis cerebral: desarrollo de nuevasterapias basadas en biomarcadores diana de predicción y prognosis (PETRABRAINMET)

Co-investigators: Noemi Vidal, Miguel Gil-Gil

Period: 2015-2017

 

Agency: Fondos Investigación Sanitaria PI07/0802

Title: Identificación de factores de riesgo clínicos, neurofisiológicos y metabólicos en lasneuropatías inducidas por platinos y taxanos.

IP: Jordi Bruna

N Participants:5

Period: 2008-2010

Amount:47553

 

Agency: Fundació Marató de TV3

Title: Safety assessment and identification of clinical, neurophysiological and functionalneuroimage risk factors to develop cognitive impairment by profilactic whole brain radiotherapyin patients with oat-cell cancer

IP: Antoni Rodriguez-Fornells/ Jordi Bruna

N Participants: 5

Period: 2011-2014

Amount: 200000

 

Agency: Grupo Español de Investigación en Neurooncología

Title: Posible Utilidad de la Resonancia Magnética Preradioterapia Precoz (PRMR) para elSeguimiento de los Gliomas de Alto Grado

IP: Carles Majós

N Participants:5

Period: 2013-2015

Amount: 15000

 

Agency: Ayudas del Ministerio de Ciencia y Tecnología (MCYT)

Title: Molecular imaging of high grade glioma for improving response to treatment (MOLIMAGLIO). SAF2014-52332-R

IP: Carles Majós, co-investigator

Period: 2015-2017

imatge personal
 

Group leader

Jordi Bruna
Telephone  
+34 932607744
E-mail  
jbruna@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell